CeloNova
CeloNova Biosciences was a San Antonio-based medical device company that developed PzF nanocoated interventional cardiology and endovascular products, including Embozene and Tandem Microspheres for oncology/radiology embolic therapy. Its interventional radiology business was acquired by Boston Scientific in 2015.
- Company typePrivate
- Founded2000
- HeadquartersSan Antonio, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CeloNova does
CeloNova Biosciences was a San Antonio, Texas-based medical device company founded in 2000 that developed, manufactured, and marketed interventional cardiology and endovascular products. Its commercial portfolio centered on the proprietary Polyzene-F (PzF) nanocoating technology — an inorganic perfluorinated polymer applied as a thin-film coating to blood-contacting medical devices to reduce inflammation, thrombus formation, and unwanted tissue reaction. The company commercialized PzF-coated products including Embozene Microspheres and Tandem Microspheres for embolic therapy in oncology/radiology applications, and the COBRA PzF NanoCoated Coronary Stent for interventional cardiology.
CeloNova's go-to-market focused on specialty interventional radiology and cardiology channels, with no publicly disclosed pricing model or volume-tier structure. The customer base was narrowly concentrated in oncology/radiology embolic therapy for the microsphere products and interventional cardiology for the coronary stent. In 2015, Boston Scientific acquired CeloNova's interventional radiology business, including the Embozene and Tandem Microspheres product lines, transferring the company's primary commercial assets into Boston Scientific's global sales channel. Following the divestiture, the PzF technology platform appears to have been repositioned through a successor/affiliated entity (Alta Biomed) as a contract PzF coating and hemocompatibility testing services business serving third-party medical device developers across vascular, structural heart, and catheter-based applications.
CeloNova firmographics
Firmographics- Name
- CeloNova
- Legal name
- CeloNova Biosciences
- Website
- https://celonova.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- CeloNova Biosciences was a San Antonio-based medical device company that developed PzF nanocoated interventional cardiology and endovascular products, including Embozene and Tandem Microspheres for oncology/radiology embolic therapy. Its interventional radiology business was acquired by Boston Scientific in 2015.
- Ownership category
- akta.pro rank
CeloNova industry classification
Industry- Product category
- Interventional Cardiology and Endovascular Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
Keywords
Where CeloNova is headquartered
LocationHeadquarters
- HQ city
- San Antonio
- HQ country
- United States
- HQ region
- North America
Markets served
CeloNova business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
CeloNova product offering
Product offeringCore offering
CeloNova BioSciences developed, manufactured, and marketed interventional cardiology and endovascular medical devices, with a product portfolio centered on PzF (Polyzene-F) nanocoated embolic microspheres for oncology/radiology procedures. Its flagship products — Embozene Microspheres and Tandem Microspheres — were spherical, tightly calibrated hydrogel microspheres coated with an inorganic perfluorinated polymer designed to reduce inflammation and unwanted tissue reaction in blood-contacting applications.
Product overview
CeloNova (now primarily known through historical product references) was a medical device company focused on interventional radiology and cardiovascular products. The company's product portfolio centered on PzF (Polyzene-F) nanocoated microspheres for embolic therapy, including Embozene Microspheres for oncology/radiology applications and Tandem Microspheres for drug elution applications. Both product lines were acquired by Boston Scientific in 2015. These products utilized proprietary PzF thin-film coating technology designed to reduce inflammation and unwanted tissue reaction in blood-contacting medical device applications.
Differentiator
Problem solved
Functional benefit
Brands
- Embozene Microspheres: PzF nanocoated spheres designed to be virtually invisible to the body, reducing inflammation and unwanted tissue reaction. Product acquired by Boston Scientific in 2015.
- Tandem Microspheres
Products and services
- Embozene Microspheres PzF nanocoated microspheres designed to be virtually 'invisible' to the body, reducing inflammation and unwanted tissue reaction. Spherical, tightly calibrated, biocompatible, non-resorbable hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene-F). Used for embolic therapy in oncology and radiology applications.
- Tandem Microspheres (TANDEM®) Spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with Polyzene-F. Available in a range of sizes suitable for embolic therapy, including drug elution applications.
Companies that use CeloNova
Customer profileSegments1 record
Ideal customer profiles1 record
CeloNova technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CeloNova partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights3 records
CeloNova competitors and assessment
Company assessmentDirect peers
- Biocoat: Biocoat specializes in hydrophilic and biomimetic coatings for medical devices, including contract coating services and coating equipment. Closely parallels Alta Biomed's OEM-focused contract coating and testing model for vascular and catheter-based devices.
- Merit Medical Systems: Merit Medical is a major manufacturer of embolization particles (EmboGold, Bearing nsPVA, QuadraSphere), microcatheters, and interventional oncology/radiology devices. Directly comparable to CeloNova's legacy Embozene microsphere franchise in embolic therapy.
- Surmodics: Surmodics is a leading provider of surface modification coatings (hydrophilic, drug-delivery, hemocompatible) for medical devices including catheters, guidewires, and vascular implants. Directly comparable to CeloNova/Alta Biomed's PzF coating services franchise and overlapping customer base of medical device OEMs.
- Hydromer: Hydromer develops and applies hydrophilic and antithrombogenic coatings for catheters, guidewires, and other blood-contacting devices. Directly comparable as a coating technology provider serving the same interventional/cardiovascular device OEMs.
- Sirtex Medical: Sirtex develops and markets SIR-Spheres Y-90 resin microspheres for radioembolization in liver oncology. Comparable to CeloNova's Embozene/Tandem Microspheres as a microsphere-based interventional oncology/radiology therapy company.
Broad incumbents
- DSM Biomedical (dsm-firmenich): DSM Biomedical supplies a broad portfolio of biomaterials and coatings (including hydrophilic coatings and drug-delivery polymers) used in vascular, orthopedic, and other implantable medical devices. Overlaps with PzF in surface modification for blood-contacting applications but serves a much wider portfolio.
- Boston Scientific: Boston Scientific acquired CeloNova's interventional radiology business (Embozene/Tandem Microspheres) in 2015 and is a major interventional cardiology and oncology player. Operates as both the acquirer of CeloNova's legacy products and a broad incumbent across the same clinical specialties CeloNova originally targeted.
- Medtronic: Medtronic is a global leader in interventional cardiology (stents, including drug-eluting), endovascular, and embolization devices. Comparable as a broad incumbent across CeloNova's interventional cardiology and oncology/radiology end markets.
- Terumo: Terumo manufactures interventional cardiology, endovascular, and oncology devices, including hydrophilic-coated guidewires, catheters, and embolization products. Broad incumbent overlap with CeloNova's interventional cardiology and oncology product lines and coating use cases.
Emerging players
- Covalon Technologies: Covalon develops antimicrobial and biocompatible coating technologies for medical devices and wound care. Comparable as an emerging specialty coatings company targeting blood-contacting and infection-control applications with a smaller commercial footprint than incumbents.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
CeloNova social profiles
Digital presenceCeloNova financial estimates
Financial estimateRevenue estimate
Valuation estimate
CeloNova leadership team
Management profileNumber of profiles
CeloNova funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CeloNova M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CeloNova
What does CeloNova do?
CeloNova BioSciences developed, manufactured, and marketed interventional cardiology and endovascular medical devices, with a product portfolio centered on PzF (Polyzene-F) nanocoated embolic microspheres for oncology/radiology procedures. Its flagship products — Embozene Microspheres and Tandem Microspheres — were spherical, tightly calibrated hydrogel microspheres coated with an inorganic perfluorinated polymer designed to reduce inflammation and unwanted tissue reaction in blood-contacting applications.
When was CeloNova founded?
CeloNova was founded in 2000. It employs 51 to 100 people.
Where is CeloNova based?
CeloNova is headquartered in San Antonio, United States, in the North America region.
Who are CeloNova's main competitors?
Direct peers on record are Biocoat, Merit Medical Systems, Surmodics, Hydromer and Sirtex Medical. Broad incumbents are DSM Biomedical (dsm-firmenich), Boston Scientific, Medtronic and Terumo. Covalon Technologies is listed as an emerging player.
Does CeloNova have an API?
No public API is recorded for CeloNova.
What industry is CeloNova in?
CeloNova's product category is Interventional Cardiology and Endovascular Medical Devices. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS). Its NAICS code is 3391 and its SIC code is 3841.